node-negative

node-negative

Oncology adjective Referring to a cancer that has not spread to regional lymph nodes. See Axillary tail.
References in periodicals archive ?
The primary objective of TAILORx is to more precisely determine the effect of chemotherapy, if any, for women with node-negative, hormone receptor-positive disease and Oncotype DX Breast Recurrence Score results of 11 to 25.
1] These shifts include the transition from routine axillary lymph node dissection (ALND) to sentinel lymph node biopsy (SLNB) in node-negative patients, and the transition from routine mastectomy to breast-conserving therapy.
Are we throwing away the valued concept of the early diagnosis of node-negative breast cancer?
The MetaSite Breast test is intended for use in patients with early stage (stage 1-3), invasive breast cancer who have node-negative or node positive, Hormone Receptor -positive, HER2-negative disease.
1) The 5-year disease-free survival of patients with LN metastasis is reduced by up to 48%, depending on the T stage and the number of positive LNs, as compared to patients with node-negative cancer.
Moreover in node-negative BC, tumor size becomes the most significant prognostic factor for decisions regarding adjuvant therapy.
The results come from an international research collaboration called MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy).
In a series of 226 patients with a total of 240 breast tumors, there was no significant difference between patients with node-positive or node-negative disease in the rate of conversion from a planned nipple-sparing procedure to a skin-sparing procedure, reported Dr.
Treatment of Patients with Clinically Lymph Node-negative Squamous Cell Carcinoma of the Oral Cavity.
We found that use of the assay was largely restricted to the populations for which it was initially approved in 2005, namely women with estrogen receptor-positive, lymph node-negative, stage I or II breast cancer," the investigators said (JAMA Oncol.
Using a 70-gene signature screening tool for adjuvant chemotherapy decisions cost significantly more than did other methods, including giving chemotherapy to all patients, but did not confer any additional benefits in survival or quality of life, for women with node-negative breast cancer.
Our study reveals that the number of lymph nodes analyzed is a significant variable that affects survival in both node-negative and node-positive patients.